X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Piramal Healthcare: Can it stick to vision 2015? - Outside View
 
 
Piramal Healthcare: Can it stick to vision 2015?

The bombshell that Piramal dropped

The annual report of Piramal Healthcare for the 12 months ended March 2010 starts with the vision statement to become the most admired Indian pharma company with leadership in market share, research and profits etc. Among the several stated objectives, is being the partner of choice for global pharma companies. One does not know whether the company achieved its intended goal, but Ajay Piramal delivered a coup of sorts when he translated a part of his vision into reality by announcing the sale of the company's domestic pharma portfolio for US$ 3.7 bn to Abbott Laboratories. Abbott was one of the many MNC suitors for the business, and paid top dollar for the acquisition. Piramal Healthcare will now consist of its pharma export sales, including the production units catering to pharma exports, and the consumer goods portfolio and, bulk drug production.

Many M&As make it what it is today

For those not in the know, the mellifluous company is today an amalgam of many pharma, and some non pharma companies too - including Roche, Nicholas, Rhone- Poulenc, Boehringer Manheim, Hoechst Marrion Roussel Research Centre, Aventis Research, ICI Pharma, Sarabhai Piramal, Rhodia UK, Minrad USA, Sumitra Pharma and, Gujarat Glass at some point. And, full marks to Ajay's bushwhacking entrepreneurial spirit in putting it all together and creating value from these acquisitions. Some would say that he was lucky to be in the right place at the right time. The company is still a pygmy by international standards though. Its plans to also become an MNC operationally, if any, seem to be fluctuating wildly. In FY10 sales billed outside India by Piramal Healthcare was a mere 14% of all sales, down from 25% in the preceding year. Simultaneously, there is also a significant drop in carrying amounts of segment assets outside India. Its international operations too merit little attention. And, its attempts to become an international player by setting up pharma manufacturing units abroad are as yet a non starter. Piramal's entrepreneurial skills also plumb the depths of probity but more of that later.

Significance of outsourced sales

The fact of the matter is also that, inspite of all the M&As engineered by the management over the years, the significance of bought out sales in overall sales is a growing factor. Apparently, given the cost structure it is cheaper to outsource from more cost effective smaller manufacturers. Bought out sales of creams, vials, tablets, liquids and the like accounted for 37% of all sales of Rs 27 bn in the latest accounting year, against 29% in the preceding year. Bought out sales from its subsidiaries and associates was only a mere 2% of all sales. Not that the company is lacking in subsidiaries. Like all Indian multinationals Piramal Healthcare has a passion to 'procreate' them and ends up with a surfeit of them. How many subsidiaries it has depends on which page of the report one is looking at, partly because there are subsidiaries of subsidiaries to contend with.

Subsidiaries by the dozen

The best estimate is that there are 20 subsidiaries, including subsidiaries of subsidiaries, not including another 7 companies which come under the category of other related parties and, 3 joint ventures. It appears to have set up manufacturing facilities in the UK, France, The US, Canada, and other 'abroad' country. Many of the subsidiaries can be classified as no gooders with no transactions to boot. Quite some others belong to the investment company fraternity, incorporated in exotic locales, and live off on moneys borrowed from the parent and who then invest in the immediate group. The parent has been kind enough to give the brief working details of 15 of the subsidiaries and also of their offspring. Fully half of them have no revenue or have revenues which are laughable. Of the remaining, barring one, none of the others could report positive bottom line figures. So who cares anyway?

Where some of these subsidiaries excel is, in being active participants in the juggling of group's cash flow, which as one may have guessed is fairly one sided. During the year the finance including loans and equity granted by the parent to its siblings came to a neat Rs 19 bn, against a marginally higher Rs 20.5 bn in the preceding year. It earned an interest of around 6% on this advance on a rough basis, which is slightly lower than the 7% that it got in the preceding year. What other business revenues the parent company generated if any from this exercise is not readily known. The real trick here is that during the year the parent advances large sums primarily to its subsidiary, PHL Fininvest, and at year end it is returned by PHL to the parent, and the cycle commences all over again at the start of the next year. Having subsidiary companies also implies having to foot other costs too. The guarantees given by the parent on behalf of subsidiaries and on performance guarantees at year end was a cool Rs 14 bn (against Rs 8.6 bn).

Paltry returns on equity investments

Its return in the form of dividends from its investments in subsidiaries and JVs etc are another sore point. On a rough equity investment base of Rs 1.6 bn, it earned a return of Rs 78 m in the latest year. It will be of help if the directors' report is a little more forthcoming on the need for its myriad investments and how the numerous interest free loans and other freebies extended to its subsidiaries is going to help the company on an ongoing basis. Managements should not be allowed to run riot like our state governments and the Union Government.

Vision 2015

Piramal now says his vision is to become one of the world's top five contract research and manufacturing companies by 2015. The company's buyout compass will now be centred on niche global companies will the moolah that it got from the sale of its domestic formulation business, with a focused revenue of over a billion dollars he adds. Given his past record that does not appear to be a very tall order but it may imply having to dismantle his present operations strategy on the foreign front which appears totally unfocussed.

Disclosure: Please note that I am not a shareholder of this company

This column "Cool Hand Luke" is written by Luke Verghese. Luke has been a business journalist, financial analyst and knowledge management head with a professional experience of more than 20 years. An avid watcher of the stock market, he has written extensively on stock market trends. His articles have featured in Business Standard, Financial Express and Fortune India amongst others. He has also been the Deputy Editor, Fortune India and the Financial Editor of The Business and Political Observer.

Disclaimer:
The views mentioned above are of the author only. Data and charts, if used, in the article have been sourced from available information and have not been authenticated by any statutory authority. The author and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views constitute only the opinions and do not constitute any guidelines or recommendation on any course of action to be followed by the reader. Please read the detailed Terms of Use of the web site.
Equitymaster Agora Research Private Limited

 

Equitymaster requests your view! Post a comment on "Piramal Healthcare: Can it stick to vision 2015?". Click here!

  
 

More Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 18, 2017 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS